QC
PTGX icon

Quadrature Capital’s Protagonist Therapeutics PTGX Stock Holding History

Quadrature Capital’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$640K Buy
+5,222
New +$545K 0.01% 919
2025
Q2 		– Sell
-26,061
Closed -$1.26M – 1396
2025
Q1 		$1.26M Buy
+26,061
New +$1.09M 0.03% 379

Other funds holding PTGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Quadrature Capital's PTGX Position: Q2 2026 in Review

Quadrature Capital opened a new position in Protagonist Therapeutics (PTGX) in Q2 2026: 5,222 shares worth $640K. The stake represents 0.01% of the portfolio and ranks #919 among its holdings. This is a return to the name: Quadrature Capital previously reported a position in PTGX as recently as Q1 2025.

Quadrature Capital first reported a position in PTGX in Q1 2025 and has held it in 2 quarters since. The position peaked at $1.26M in Q1 2025. 343 funds tracked by Wall St. Rank hold PTGX as of Q2 2026.

  • Quadrature Capital held 5,222 shares of Protagonist Therapeutics worth $640K as of Q2 2026.
  • Protagonist Therapeutics was a new Quadrature Capital position in Q2 2026.
  • Protagonist Therapeutics made up 0.01% of Quadrature Capital's portfolio in Q2 2026, its #919 holding.
  • Quadrature Capital first reported a position in Protagonist Therapeutics in Q1 2025 and has held it in 2 quarters since.
  • Quadrature Capital's Protagonist Therapeutics position peaked at $1.26M in Q1 2025.
  • 343 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2026.

Based on Quadrature Capital's 13F filing for Q2 2026, filed 7 Aug 2026.